Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals' Manufacturing Facility in Monroe, North Carolina19-06-2018
19-06-2018
Glenmark gets USFDA nod for contraceptive drugs
Glenmark Pharmaceuticals has received final approval from the US health regulator for generic versions of Loestrin tablets, used to prevent pregnanc06-06-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for HAILEYTM 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/30 mcg) and HAILEYTM Fe 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets, 1.5 mg/30 mcg)06-06-2018
From Cipla to Glenmark, pharma companies' double-digit growth in doubt
Govt's proposed changes in pricing policy could play spoilsport04-06-2018
US price erosion: Pressure on Glenmark's business to continue
Company expects 10-12 per cent price erosion to continue in America31-05-2018
Glenmark Pharma drops to over 3-month low
Glenmark Pharmaceuticals dropped the most in over 3 months. The stock fell nearly 5 per cent to Rs 505.5, its lowest since May 22.The stock posted i30-05-2018
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Nomination & Remuneration Committee of the Company, at its meeting held on May 29, 2018 has granted 41,666 stock options under Employee Stock Options Scheme, 2016.29-05-2018
Announcement under Regulation 30 (LODR)-Acquisition
In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with corresponding circulars and notifications issued thereunder, it is hereby informed to you that the Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 29, 2018, approved the draft share purchase agreement to acquire 100% stake in Zorg Laboratories Private Limited...29-05-2018
Corporate Action-Board approves Dividend
The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 29, 2018 has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2017 - 2018 subject to the approval of the Shareholders at the ensuing Annual General Meeting.29-05-2018
Board Meeting-Outcome of Board Meeting
Sub-Outcome of the Board Meeting held on May 29, 201829-05-2018